Gene Therapy (PF-06939926) for Duchenne Muscular Dystrophy
What You Need to Know Before You Apply
What is the purpose of this trial?
The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but it excludes those who have had certain treatments to increase dystrophin expression in the past 6 months or have used oral glucocorticoids or other immunosuppressive agents for DMD.
How is the treatment PF-06939926 for Duchenne Muscular Dystrophy different from other treatments?
PF-06939926 is a gene therapy that uses a virus to deliver a modified version of the dystrophin gene to muscle cells, aiming to restore the production of dystrophin, a protein missing in Duchenne Muscular Dystrophy. This approach is unique because it targets the root cause of the disease by addressing the genetic defect, unlike traditional treatments that only manage symptoms.12345
What data supports the effectiveness of the treatment PF-06939926 for Duchenne Muscular Dystrophy?
Gene therapy, like PF-06939926, is being explored for Duchenne Muscular Dystrophy, with research showing progress in similar treatments using gene transfer techniques that improve muscle function in animal models. While specific data on PF-06939926 is not provided, advancements in gene therapy for similar conditions suggest potential effectiveness.13567
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
This trial is for boys with a confirmed diagnosis of Duchenne Muscular Dystrophy (DMD) who haven't had gene therapy before. They must have normal blood counts and liver/kidney function, no specific genetic mutations in the dystrophin gene, and no recent treatments aimed at increasing dystrophin expression.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single IV infusion of PF-06939926 gene therapy
Follow-up
Participants are monitored for safety and dystrophin expression after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PF-06939926
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University